Search in:

Patient Preference and Adherence Volume 12, 2018 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database

Philip A Baer1 Baer Weinberg MPC, Scarborough, ON

Guy Aumais2 Department of Medicine, Université de Montréal, Gastro-enterology Unit, Hôpital Maisonneuve-Rosemont, Montréal, QC

Emmanuel M Ewara3 Government Affairs and Market Access, Janssen Inc., Toronto, ON

Majed Khraishi4 Medical Affairs, Janssen Inc., Toronto, ON

A Marilise Marrache5 Faculty of Medicine, Division of Rheumatology, Memorial University of Newfoundland and Nexus Clinical Research, St John’s, NL

Remo Panaccione6 Inflammatory Bowel Disease Unit, Department of Medicine, University of Calgary, Calgary, AB

John P Wade7 Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, BC

John K Marshall8 Department of Medicine, Division of Gastroenterology, McMaster University and Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada, [email protected]Correspondence[email protected]

show all

Pages 1805-1814 | Published online: 18 Sep 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

SmolenJSAletahaDMcInnesIBRheumatoid arthritisLancet2016388100552023203827156434
PubMed Web of Science ®Google Scholar
BraunJSieperJAnkylosing spondylitisLancet200736995701379139017448825
PubMed Web of Science ®Google Scholar
AnandarajahAPRitchlinCTThe diagnosis and treatment of early psoriatic arthritisNat Rev Rheumatol200951163464119806150
PubMed Web of Science ®Google Scholar
BresslerBMarshallJKBernsteinCNClinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensusGastroenterology201514851035105825747596
PubMed Web of Science ®Google Scholar
GomollónFDignassAAnneseV3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical managementJ Crohns Colitis201711132527660341
PubMed Web of Science ®Google Scholar
BluettJMorganCThurstonLImpact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortRheumatology201554349449925213131
PubMed Web of Science ®Google Scholar
GisbertJPArredondoMChaparroMDrug survival and reasons for discontinuation of anti-TNF therapy in inflammatory bowel disease (IBD) in clinical practicePoster presented at: European Crohn’s and Colitis Organisation Annual Meeting2014Copenhagen, Denmark
Google Scholar
CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
PubMed Web of Science ®Google Scholar
IQVIA: Private DrugPlans (PDP), Ontario Public Drug Programs (OPDP), Régie de l’assurance maladiedu Québec (RAMQ) Available from: www.iqvia.comAccessed December 16, 2016
Google Scholar
ChoiCHSongIDKimYHEfficacy and safety of infliximab therapy and predictors of response in Korean patients with Crohn’s disease: a nationwide, multicenter studyYonsei Med J20165761376138527593865
PubMed Web of Science ®Google Scholar
SchnitzlerFFidderHFerranteMMucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s diseaseInflamm Bowel Dis20091591295130119340881
PubMed Web of Science ®Google Scholar
Peyrin-BirouletLSalleronJFilippiJAnti-TNF monotherapy for Crohn’s disease: a 13-year multicentre experienceJ Crohns Colitis201610551652426802084
PubMed Web of Science ®Google Scholar
FavalliEGSelmiCBeccioliniAEight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysisArthritis Care Res2017696867874
Web of Science ®Google Scholar
SoubrierMPereiraBFrayssacTPsoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, FranceClin Exp Rheumatol20163461059106427607233
PubMed Web of Science ®Google Scholar
NeoviusMArkemaEVOlssonHDrug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximabAnn Rheum Dis201574235436024285495
PubMed Web of Science ®Google Scholar
GlintborgBSørensenIJLoftAGA nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnn Rheum Dis20177681426143128473425
PubMed Web of Science ®Google Scholar
BrodszkyVRenczFPéntekMBajiPLakatosPLGulácsiLA budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and SlovakiaExpert Rev Pharmacoecon Outcomes Res201616111912526162458
PubMed Web of Science ®Google Scholar
MarshallJKBessetteLThorneCImpact of the adalimumab patient support program’s care coach calls on persistence and adherence in Canada: an observational retrospective cohort studyClin Ther201840341542929519714
PubMed Web of Science ®Google Scholar
Remicade® (infliximab) [product monograph]TorontoON: Janssen Inc2017
Google Scholar
HuangVWChangHJKroekerKIManagement of inflammatory bowel disease during pregnancy and breastfeeding varies widely: a need for further educationCan J Gastroenterol Hepatol20162016619327527725926
PubMed Web of Science ®Google Scholar
FinckhANetoDIannoneFThe impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesRMD Open201511e00004026509062
PubMed Web of Science ®Google Scholar
RummanACandiaRSamJJPublic versus private drug insurance and outcomes of patients requiring biologic therapies for inflammatory bowel diseaseCan J Gastroenterol Hepatol20172017736593728239601
PubMed Web of Science ®Google Scholar
GlintborgBOstergaardMKroghNSClinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO RegistryArthritis Rheum20136551213122323460467
PubMed Web of Science ®Google Scholar
FagerliKMLieEvan der HeijdeDSwitching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD studyAnn Rheum Dis201372111840184423562987
PubMed Web of Science ®Google Scholar
StarrMKeystoneEFaraawiRPredictors of treatment retention among patients with rheumatoid arthritis or ankylosing spondylitis treated with Remicade® (infliximab) for long-term in Canadian real-worldPoster presented at: American College of Rheumatology Annual MeetingNovember 11–16; 2016Washington, DC
Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date